FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569291750> ?p ?o ?g. }

• W1569291750 abstract "BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers. This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6-mercaptopurine (6MP) 55 mg/m2 per day, and methotrexate 15 mg/m2 per week in patients with advanced breast or ovarian cancer, ECOG PS 0–2, progressing after ≥ one prior regimen and known to bear a BRCA1/2 germ line mutation. Accrual was planned in two stages, with treatment continuing until progression or unacceptable toxicity; in the first, if less than 3/30 evaluable patients respond at 8 weeks after commencing treatment, the trial will be stopped for futility; if not, then accrual would proceed to a second stage, in which if more than 9/65 evaluable patients are found to respond at 8 weeks, the treatment will be regarded as potentially effective and a phase III trial considered subject to satisfactory safety and tolerability. The primary outcome is objective response at 8 weeks, defined by RECISTS v1.1 as complete response, partial response or stable disease. Secondary outcomes include safety, progression- free and overall survival, and quality of life. This study aims to investigate whether 6MP might be an effective treatment for BRCA deficient tumours even after the development of resistance to PARP inhibitors or platinum drugs. The study has surpassed the first stage analysis criteria of more than 3 out of 30 evaluable patients responding at 8 weeks, and is currently in the second stage of recruitment. NCT01432145 http://www.ClinicalTrials.gov" @default.
• W1569291750 created "2016-06-24" @default.
• W1569291750 creator A5000829593 @default.
• W1569291750 creator A5009351129 @default.
• W1569291750 creator A5010013600 @default.
• W1569291750 creator A5016742379 @default.
• W1569291750 creator A5037067626 @default.
• W1569291750 creator A5045763991 @default.
• W1569291750 creator A5050804752 @default.
• W1569291750 creator A5053795862 @default.
• W1569291750 creator A5072708115 @default.
• W1569291750 creator A5074839524 @default.
• W1569291750 creator A5075349431 @default.
• W1569291750 date "2014-12-01" @default.
• W1569291750 modified "2023-10-09" @default.
• W1569291750 title "A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol" @default.
• W1569291750 cites W1495272710 @default.
• W1569291750 cites W1964969943 @default.
• W1569291750 cites W1973268287 @default.
• W1569291750 cites W1976453250 @default.
• W1569291750 cites W1977452842 @default.
• W1569291750 cites W2009007206 @default.
• W1569291750 cites W2065849886 @default.
• W1569291750 cites W2067117419 @default.
• W1569291750 cites W2078270553 @default.
• W1569291750 cites W2095069804 @default.
• W1569291750 cites W2096466633 @default.
• W1569291750 cites W2114787582 @default.
• W1569291750 cites W2150628057 @default.
• W1569291750 cites W2160234594 @default.
• W1569291750 cites W2162157249 @default.
• W1569291750 cites W2171972386 @default.
• W1569291750 doi "https://doi.org/10.1186/1471-2407-14-983" @default.
• W1569291750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4301834" @default.
• W1569291750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25526776" @default.
• W1569291750 hasPublicationYear "2014" @default.
• W1569291750 type Work @default.
• W1569291750 sameAs 1569291750 @default.
• W1569291750 citedByCount "11" @default.
• W1569291750 countsByYear W15692917502015 @default.
• W1569291750 countsByYear W15692917502016 @default.
• W1569291750 countsByYear W15692917502018 @default.
• W1569291750 countsByYear W15692917502019 @default.
• W1569291750 countsByYear W15692917502022 @default.
• W1569291750 crossrefType "journal-article" @default.
• W1569291750 hasAuthorship W1569291750A5000829593 @default.
• W1569291750 hasAuthorship W1569291750A5009351129 @default.
• W1569291750 hasAuthorship W1569291750A5010013600 @default.
• W1569291750 hasAuthorship W1569291750A5016742379 @default.
• W1569291750 hasAuthorship W1569291750A5037067626 @default.
• W1569291750 hasAuthorship W1569291750A5045763991 @default.
• W1569291750 hasAuthorship W1569291750A5050804752 @default.
• W1569291750 hasAuthorship W1569291750A5053795862 @default.
• W1569291750 hasAuthorship W1569291750A5072708115 @default.
• W1569291750 hasAuthorship W1569291750A5074839524 @default.
• W1569291750 hasAuthorship W1569291750A5075349431 @default.
• W1569291750 hasBestOaLocation W15692917501 @default.
• W1569291750 hasConcept C104317684 @default.
• W1569291750 hasConcept C121608353 @default.
• W1569291750 hasConcept C126322002 @default.
• W1569291750 hasConcept C143998085 @default.
• W1569291750 hasConcept C182979987 @default.
• W1569291750 hasConcept C197934379 @default.
• W1569291750 hasConcept C2776694085 @default.
• W1569291750 hasConcept C2778239845 @default.
• W1569291750 hasConcept C2778375690 @default.
• W1569291750 hasConcept C2779138821 @default.
• W1569291750 hasConcept C2780194787 @default.
• W1569291750 hasConcept C2780427987 @default.
• W1569291750 hasConcept C2781413609 @default.
• W1569291750 hasConcept C502942594 @default.
• W1569291750 hasConcept C535046627 @default.
• W1569291750 hasConcept C54355233 @default.
• W1569291750 hasConcept C71924100 @default.
• W1569291750 hasConcept C82381507 @default.
• W1569291750 hasConcept C86803240 @default.
• W1569291750 hasConcept C98274493 @default.
• W1569291750 hasConceptScore W1569291750C104317684 @default.
• W1569291750 hasConceptScore W1569291750C121608353 @default.
• W1569291750 hasConceptScore W1569291750C126322002 @default.
• W1569291750 hasConceptScore W1569291750C143998085 @default.
• W1569291750 hasConceptScore W1569291750C182979987 @default.
• W1569291750 hasConceptScore W1569291750C197934379 @default.
• W1569291750 hasConceptScore W1569291750C2776694085 @default.
• W1569291750 hasConceptScore W1569291750C2778239845 @default.
• W1569291750 hasConceptScore W1569291750C2778375690 @default.
• W1569291750 hasConceptScore W1569291750C2779138821 @default.
• W1569291750 hasConceptScore W1569291750C2780194787 @default.
• W1569291750 hasConceptScore W1569291750C2780427987 @default.
• W1569291750 hasConceptScore W1569291750C2781413609 @default.
• W1569291750 hasConceptScore W1569291750C502942594 @default.
• W1569291750 hasConceptScore W1569291750C535046627 @default.
• W1569291750 hasConceptScore W1569291750C54355233 @default.
• W1569291750 hasConceptScore W1569291750C71924100 @default.
• W1569291750 hasConceptScore W1569291750C82381507 @default.
• W1569291750 hasConceptScore W1569291750C86803240 @default.
• W1569291750 hasConceptScore W1569291750C98274493 @default.
• W1569291750 hasIssue "1" @default.
• W1569291750 hasLocation W15692917501 @default.
• W1569291750 hasLocation W15692917502 @default.

• next